ID
22207
Beskrivning
Study part: 60 Day Post- Treatment Serious Adverse Events. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Nyckelord
Versioner (1)
- 2017-05-23 2017-05-23 -
Rättsinnehavare
Roche
Uppladdad den
23 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS Roche H0650g Breast Cancer
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS
- StudyEvent: ODM
Similar models
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS
- StudyEvent: ODM
C0877248 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])